Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-27
2008-08-26
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C514S326000, C546S199000, C546S201000, C546S212000
Reexamination Certificate
active
07417058
ABSTRACT:
The present invention is related to benzsulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzsulfonamide derivatives. Said benzsulfonamide derivatives are ef-ficient modulators of the JNK pathway, they are in particular efficient and selective in-hibitors of JNK 2 and 3. The present invention is furthermore related to novel benzsul-fonamide derivatives as well as to methods of their preparation (I). The compounds of formula I according to the present invention being suitable pharma-ceutical agents are those wherein Ar1 is a substituted or unsubstituted aryl or heteroaryl group. X is O or S, preferably O.R1 is hydrogen or a C1-C6-alkyl group, preferably H.R2 is hydrogen, —COOR3, —CONR3R3′, OH, a C1-C4 alkyl substituted with an OH group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt; n is either 0 or 1, preferably 1.
REFERENCES:
patent: 3812144 (1974-05-01), Dietrich et al.
patent: 5744320 (1998-04-01), Sherf et al.
patent: 2004/0053917 (2004-03-01), Halazy et al.
patent: 2004/0077632 (2004-04-01), Halazy et al.
patent: 2004/0077854 (2004-04-01), Halazy et al.
patent: 98 49188 (1998-11-01), None
Database HCA ′Online! Chemical Abstracts Service, Columbus, OH, US; abstract No. 125:2165, XP002162517, 1996.
Roger J. Davis: “Signal transduction by the JNK Group of MAP kinases” Cell, vol. 103, pp. 239-252, 2000.
Yi-Rong Chen et al.: “The c-Jun N-terminal kinase pathway and apoptotic signaling” International Journal of Oncology, vol. 16, pp. 651-662 2000.
YT Ip et al.: “Signal transduction by the c-Jun N-terminal kinase (JNK) from c-Jun N-terminal kinase (JNK) from inflammation to development” Curr Opin Cell Biol, vol. 10, pp. 205-219, 1998.
S. Leppa et al.: “Diverse functions of JNK signalling and c-Jun in stress response and apoptosis” Oncogene, vol. 18, No. 45, pp. 6158-6162 1999.
A. Minden et al.: “Regulation and function if the JNK subgroup of MAP kinases” Biochim Biophys ACTA, vol. 1333, pp. F85-F104 1997.
A.J. Whitmarsh et al.: “Transcription factor AP-1: regulation by mitogen activated protein kinases signal transduction pathways” , J. Mol, Med., vol. 77, pp. 589-607 1996.
S. Gupta et al.: “Selective interaction of JNK protein kinase isoforms with transcription factors” The EMBO Journal, vol. 158, No. 11, pp. 2760-2770 1996.
D. Derek et al.: “Absence of excitotoxicity- induced apoptosis in the hippocampus of mice lacking the Jnk3 gene” Nature, vol. 389, pp. 865-876 1997.
Loel H. Martin et al.: “Developmental expression in the mouse nervous system of the p493F12 SAP kinase” Molecular Brain Research, vol. 35, pp. 47-57 1996.
Y. Kumagae et al.: “Human c-Jun N-terminal kinase expression and activation in the nervous system” Molecular Brain Research, vol. 67, pp. 10-17, 1999.
Calin D. Dumitru et al.: “TNF-alpha induction by LPS is regulated posttranscriptionally via a Tp12/ERK-dependent pathway” Cell, vol. 103, pp. 1071-1083, 2000.
Z. Han et al.: “C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis” The Journal of Clinical Investigation, vol. 108, No. 1, pp. 73-81, 2001.
H. Nishina et al.: “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes” Jounrnal of Experimental Medicine, vol. 186, No. 6, pp. 941-953, 1997.
Stephan J. Kempiak et al.: “The Jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the IB kinase cascade” The Journal of Immunology, vol. 162, pp. 3176-3187, 1999.
S.M. De La Monte et al.: “Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells” J. Alzheimer's Dis., vol. 2, No. 3-4, pp. 261-281, 2000.
X. Zhu: “Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease” Journal of Neurochemistry, vol. 76, pp. 435-441, 2001.
T. Force et al.: “Stress-activated protein kinases in cardiovascular diseas” Circulation Research, vol. 78, pp. 947-953 1996.
S. Kim et al.: “Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery” Circulation, vol. 97, pp. 1731-1737 1998.
Q. Xu et al.: “Acute hypertension activates mitogen-activated protein kinases in arterial wall” The Journal of Clinical Investigation, vol. 97, No. 2, pp. 508-514 1996.
M.A. Bogoyevitch et al.: “Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart” Circulation Research, vol. 79, pp. 163-173, 1996.
CM Pombo et al.: “The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by Ischemia and reperfusion” J. Biol. Chem., vol. 42, pp. 26546-26551, 1994.
I. Onishi et al.: “Activation of c-Jun N-terminal kinase during ischemia and reperfusion in mouse liver” FEBS Letters, vol. 420, pp. 201-204 1997.
R. Safirstein: “Renal stress response and acute renal failure” Adv. Ren. Replace Ther., vol. 4, No. 2 Suppl 1, pp. 38-42 1997.
L. Butterfield et al.: “C-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation” The Journal of Biological Chemitry, vol. 272, No. 15, pp. 10110-10116, 1997.
M. Hu et al.: “JNK2 and JNK3 are p53 N-terminal serine 34 kinases” Oncogene, vol. 15, pp. 2277-2287 1997.
X. Xu et al.: “Constitutively activated JNK is associated with HTLV-1 mediated tumorgenesis” Oncogene, vol. 13, pp. 135-142 1996.
YR Chen et al.: “The c-Jun N-terminal kinase pathway and apoptotic signaling” Int. J. Oncol., vol. 16, No. 4, pp. 651-662 2000.
T.C. Harding et al.: “Inhibition of JNK by overexpression of the JNK binding domain of JIP-1 prevents apoptosis in sympathetic neurons” The Journal of Biological Chemistry, vol. 276, No. 7, pp. 4531-4534, 2001.
AF Abdel-Magid et al.: “Reductive amination of aldehves and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures” Journal of Organic Chemistry, vol. 61, pp. 3849-3862, 1996.
L. Xu et al.: “Assess the in-vivo activation of signal transduction pathways with Pathdetect® reporting systems” Strategies, vol. 14, No. 1, pp. 1-3 2001.
S. Xu et al.: “Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain” Proc. Natl. Acad Sci. USA, vol. 93, pp. 5291-5295, 1996.
M. Guha et al.: “LPS induction of gene expression in human monocytes” Cellular Signalling, vol. 13, pp. 85-94 2001.
A. Fomsgaard et al.: “Quantification and biological activities of native tumour necrosis factor from LPS-stimulated human monocytes” APMIS, vol. 98, No. 6, pp. 529-534, 1990.
J.L. Hunter et al.: “Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?” TIPS, vol. 16, pp. 123-128, 1995.
F. Block: “Global ischemia and behavioural deficits” Progress in Neurobiology, vol. 58, pp. 279-295 1999.
SC Gerhardt et al. Behavioural Neurosciences, vol. 102, pp. 301-303 1988.
L.A. Grigoryan et al. Arm. Khim. Zh., vol. 42, No. 4, p. 236-240 1989.
A.P. New et al.: Biomed. Mass. Spec., vol. 8, No. 3, p. 620-623 1989.
U.S. Appl. No. 10/088,074 filed Mar. 20, 2002, Arkinstall et al.
U.S. Appl. No. 10/088,090, filed Jun. 21, 2002, Arkinstall et al.
A.M. Manning, et al., “Targeting JNK for Therapeutic Benefit: From Junk to Gold?”, Nature,
Arkinstall Stephen J.
Biamonte Marco
Camps Montserrat
Church Dennis
Gotteland Jean-Pierre
Coleman Brenda L
Laboratoires Serono S.A.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Pharmaceutically active benzsulfonamide derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active benzsulfonamide derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active benzsulfonamide derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996261